These results show that ELTD1 is a prognostic marker of favorable outcome inhead, neck, and ovarian cancer patients, may be because increased ELTD1 expression could correlate with higher microvessel density, allowing an improved anticancer targeted drug delivery [55]. The gene discussed is ADGRL4; the disease is ovarian cancer.